133 related articles for article (PubMed ID: 32485249)
1. Chitosan and phospholipid assisted topical fusidic acid drug delivery in burn wound: Strategies to conquer pharmaceutical and clinical challenges, opportunities and future panorama.
Jyoti K; Malik G; Chaudhary M; Sharma M; Goswami M; Katare OP; Singh SB; Madan J
Int J Biol Macromol; 2020 Oct; 161():325-335. PubMed ID: 32485249
[TBL] [Abstract][Full Text] [Related]
2. Nano-engineered lipid-polymer hybrid nanoparticles of fusidic acid: an investigative study on dermatokinetics profile and MRSA-infected burn wound model.
Thakur K; Sharma G; Singh B; Chhibber S; Katare OP
Drug Deliv Transl Res; 2019 Aug; 9(4):748-763. PubMed ID: 30652257
[TBL] [Abstract][Full Text] [Related]
3. Cationic-bilayered nanoemulsion of fusidic acid: an investigation on eradication of methicillin-resistant Staphylococcus aureus 33591 infection in burn wound.
Thakur K; Sharma G; Singh B; Jain A; Tyagi R; Chhibber S; Katare OP
Nanomedicine (Lond); 2018 Apr; 13(8):825-847. PubMed ID: 29528278
[TBL] [Abstract][Full Text] [Related]
4. Comparison of silver-coated dressing (Acticoat), chlorhexidine acetate 0.5% (Bactigrass), and fusidic acid 2% (Fucidin) for topical antibacterial effect in methicillin-resistant Staphylococci-contaminated, full-skin thickness rat burn wounds.
Ulkür E; Oncul O; Karagoz H; Yeniz E; Celiköz B
Burns; 2005 Nov; 31(7):874-7. PubMed ID: 16011879
[TBL] [Abstract][Full Text] [Related]
5. Comparison of silver sulfadiazine 1%, mupirocin 2%, and fusidic acid 2% for topical antibacterial effect in methicillin-resistant staphylococci-infected, full-skin thickness rat burn wounds.
Acikel C; Oncul O; Ulkur E; Bayram I; Celikoz B; Cavuslu S
J Burn Care Rehabil; 2003; 24(1):37-41. PubMed ID: 12543989
[TBL] [Abstract][Full Text] [Related]
6. Phospholipid structured microemulsion as effective carrier system with potential in methicillin sensitive Staphylococcus aureus (MSSA) involved burn wound infection.
Chhibber T; Wadhwa S; Chadha P; Sharma G; Katare OP
J Drug Target; 2015 Dec; 23(10):943-52. PubMed ID: 26004269
[TBL] [Abstract][Full Text] [Related]
7. Chitosan-tailored lipidic nanoconstructs of Fusidic acid as promising vehicle for wound infections: An explorative study.
Thakur K; Sharma G; Singh B; Chhibber S; Patil AB; Katare OP
Int J Biol Macromol; 2018 Aug; 115():1012-1025. PubMed ID: 29680503
[TBL] [Abstract][Full Text] [Related]
8. Development of Chitosan-Based Hydrogel Containing Antibiofilm Agents for the Treatment of Staphylococcus aureus-Infected Burn Wound in Mice.
Chhibber T; Gondil VS; Sinha VR
AAPS PharmSciTech; 2020 Jan; 21(2):43. PubMed ID: 31897806
[TBL] [Abstract][Full Text] [Related]
9. Development of chitosan-collagen hydrogel incorporated with lysostaphin (CCHL) burn dressing with anti-methicillin-resistant Staphylococcus aureus and promotion wound healing properties.
Cui F; Li G; Huang J; Zhang J; Lu M; Lu W; Huan J; Huang Q
Drug Deliv; 2011 Apr; 18(3):173-80. PubMed ID: 20726806
[TBL] [Abstract][Full Text] [Related]
10. Where to from here? The treatment of impetigo in children as resistance to fusidic acid emerges.
Vogel A; Lennon D; Best E; Leversha A
N Z Med J; 2016 Oct; 129(1443):77-83. PubMed ID: 27736855
[TBL] [Abstract][Full Text] [Related]
11. Fusidic acid resistance in community isolates of methicillin susceptible Staphylococcus aureus and the use of topical fusidic acid: a retrospective case-control study.
Mason BW; Howard AJ
Int J Antimicrob Agents; 2004 Mar; 23(3):300-3. PubMed ID: 15164973
[TBL] [Abstract][Full Text] [Related]
12. Preparation, characterization and evaluation of glycerol plasticized chitosan/PVA blends for burn wounds.
Bano I; Arshad M; Yasin T; Ghauri MA
Int J Biol Macromol; 2019 Mar; 124():155-162. PubMed ID: 30439437
[TBL] [Abstract][Full Text] [Related]
13. Oral fusidic acid fails to eradicate methicillin-resistant Staphylococcus aureus colonization and results in emergence of fusidic acid-resistant strains.
Chang SC; Hsieh SM; Chen ML; Sheng WH; Chen YC
Diagn Microbiol Infect Dis; 2000 Feb; 36(2):131-6. PubMed ID: 10705056
[TBL] [Abstract][Full Text] [Related]
14. High usage of topical fusidic acid and rapid clonal expansion of fusidic acid-resistant Staphylococcus aureus: a cautionary tale.
Williamson DA; Monecke S; Heffernan H; Ritchie SR; Roberts SA; Upton A; Thomas MG; Fraser JD
Clin Infect Dis; 2014 Nov; 59(10):1451-4. PubMed ID: 25139961
[TBL] [Abstract][Full Text] [Related]
15. Fusidic acid betamethasone lipid cream.
Girolomoni G; Mattina R; Manfredini S; Vertuani S; Fabrizi G
Int J Clin Pract; 2016 May; 70 Suppl 184():4-13. PubMed ID: 27121235
[TBL] [Abstract][Full Text] [Related]
16. A novel wound dressing consisting of PVA-SA hybrid hydrogel membrane for topical delivery of bacteriophages and antibiotics.
Kaur P; Gondil VS; Chhibber S
Int J Pharm; 2019 Dec; 572():118779. PubMed ID: 31740093
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of Staphylococcus aureus to fusidic acid: Canadian data.
Rennie RP
J Cutan Med Surg; 2006; 10(6):277-80. PubMed ID: 17241597
[TBL] [Abstract][Full Text] [Related]
18. Fusidic acid-resistant Staphylococcus aureus (FRSA) carriage in patients with atopic eczema and pattern of prior topical fusidic acid use.
Sule O; Brown NM; Willocks LJ; Day J; Shankar S; Palmer CR; Burrows NP
Int J Antimicrob Agents; 2007 Jul; 30(1):78-82. PubMed ID: 17475448
[TBL] [Abstract][Full Text] [Related]
19. Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus.
Howden BP; Grayson ML
Clin Infect Dis; 2006 Feb; 42(3):394-400. PubMed ID: 16392088
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of MRSA otorrhoea: a case report.
Hunt A; Robb PJ
J Laryngol Otol; 2006 Jan; 120(1):63-4. PubMed ID: 16359141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
